Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For

News Snapshot:

PeopleImages Ascendis Pharma A/S (ASND) reported strong sequential growth of Skytrofa in the third quarter and the company raised the full-year net sales guidance range from €165-170 million to €170-175 million. While Skytrofa's uptake updates are positive and a welcome development after the very slow initial launch, quarterly sales updates are not really what investors (myself included) are waiting for. Ascendis resubmitted the NDA resubmission TransCon PTH and the assignment of the PDUFA date and the FDA's decision remains the limiting step for the next stage of value creation. There are also incremental catalysts this quarter - the phase 3...